在缺血性心脏病中寻找和治疗炎症:我们准备好了吗?
Francesco Prati1,2, Flavio Mastroianni2,3, Giulia Paoletti2
1Cardiovascular Sciences Department, San Giovanni Addolorata Hospital, Rome, Italy.
概括
系统性炎症是心血管风险的关键. 新的标记物,如介质蛋白-6 (IL-6) 和先进的成像,可以更好地检测炎症,从而有可能改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 医疗成像医学成像
背景情况:
- 系统性炎症有助于动脉样硬化和残留心血管风险.
- 高灵敏度C反应蛋白 (hsCRP) 与心血管事件相关,但特异性较低.
- 作为改进的预后工具,正在探索interleukin-6 (IL-6) 和局部炎症标志物.
研究的目的:
- 探索新的全身和局部炎症标志物用于心血管风险评估.
- 评估用于识别高风险冠状动脉病变的高级成像技术.
- 讨论针对炎症的治疗策略,以减少心血管风险.
主要方法:
- 对炎症标志物 (hsCRP,IL-6) 的研究的审查.
- 评估成像方式,包括CT-PET和光学连贯性断层扫描来检测巨细胞.
- 分析抗炎治疗策略及其对hsCRP和IL-6的影响.
主要成果:
- IL-6和心周脂肪组织显示出作为替代标记物的希望.
- 使用68Ga-DOTATATE的CT-PET和光学连贯性断层扫描对于可视化炎症非常有价值.
- 针对炎症的治疗策略,如微管抑制剂,可能会降低心血管风险.
结论:
- 新的系统性标记物 (IL-6) 和高级成像 (CT-PET) 改善了炎症的诊断.
- 针对炎症是一种潜在的治疗策略,可以减少剩余的心血管风险.
- 需要进一步的研究来澄清胆固醇在缺血性心脏病中的作用.
相关概念视频
01:17Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
385
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
385
01:38Inflammation
51.0K
Overview
51.0K
01:30Inflammatory Response I: Vascular and Cellular
10.5K
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
10.5K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80